Cochlear, a provider of implantable hearing solutions, has obtained an approval from the US Food and Drug Administration (FDA) for the Cochlear Baha 4 attract system for use in the US.
The new Baha 4 attract system is a magnetic Baha bone conduction hearing device that uses magnets to connect the sound processor to the titanium implant. The sound processor attaches to the external magnet that transmits the sound to the internal magnet hidden under the skin.
The single-point of transmission through the osseointegrated implant and Cochlear's advanced sound processor technology enables efficient conduction of sound.
Implantations of the first Baha 4 attract system in the began commenced on 26 November 2013. Until now, approximately 100 people have been implanted across the globe.
Cochlear Americas president Chris Smith noted the Baha 4 attract system sets new standards in simplicity, comfort and hearing performance for magnetic bone conduction implant systems.
"We are pleased to be bringing this new hearing option to patients who want to enjoy the benefits of the Baha System without a skin penetrating abutment. Cochlear is dedicated to being a leader in bone conduction and this important milestone further emphasizes our commitment to continuing our legacy in innovation," Smith added.
The company recently launched new Baha 4 sound processor that features the Ardium platform. The added power within the Baha 4 sound processor drives sophisticated sound technologies, true 2.4 GHz digital wireless connectivity and remote controls.
Cochlear claims it is the only company to now offer patients a choice of either a magnetic or a direct bone conduction hearing solution.
